Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment neuromuscular diseases. The company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Keros Therapeutics Inc.

In a report released today, Jason Zemansky from Bank of America Securities reiterated a Hold rating on Keros Therapeutics, with a price target of $...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	KROS	$21.51	-0.83%	367.42K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	KROS	$21.51	-0.8%	367.42K
3
4
5
6

KROS

KROS

No Data Available

Get Keros Therapeutics Inc. Data in Excel

Get Keros Therapeutics Inc. Data in Excel